RVNC•benzinga•
Needham Maintains Buy Rating for Revance Therapeutics: Here's What You Need To Know
Summary
Needham has decided to maintain its Buy rating of Revance Therapeutics (NASDAQ:RVNC) and raise its price target from $25.00 to $35.00. Shares of Revance Therapeutics are trading up 9.72% over the last 24 hours, at $27.76 per share.
Original Article
Read the full article from the original source for complete details and context.
Read Full ArticleArticle published on September 9, 2022 by benzinga